PCN90 Cost-Effectiveness Analysis of Erlotinib Versus Docetaxel, Pemetrexed for Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Russia
Nov 1, 2011, 00:00
10.1016/j.jval.2011.08.1191
https://www.valueinhealthjournal.com/article/S1098-3015(11)02753-7/fulltext
Title :
PCN90 Cost-Effectiveness Analysis of Erlotinib Versus Docetaxel, Pemetrexed for Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Russia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)02753-7&doi=10.1016/j.jval.2011.08.1191
First page :
A450
Section Title :
Cancer
Open access? :
No
Section Order :
1145